ClinicalTrials.gg
Status unknownNCT04631549Updated Dec 1, 2022

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

A Phase 1 interventional study of SHR3680 in Hepatic Impairment and Healthy Participants, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate SHR3680 in participants with different levels of liver function

02

Conditions studied

  • Hepatic Impairment
  • Healthy Participants
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Participants with mild to moderate liver impairment must meet all of the following criteria to enter the study:

  • The is signed before the trial, and the content, process and possible adverse reactions are fully understood; Be able to complete the study according to the requirements of the test scheme;
  • Only for male, subjects aged 18 to 75 years (including both ends) on the date of signing informed consent;
  • The body weight subjects is no less than 50 kg. (BMI) is in the range of 19.0 kg/m2-29.0 kg/m2 (including the critical value);
  • Primary liver disease (except for drug-induced liver injury) is necessary for patients with liver impairment, then patients with mild liver impairment ( score: 5-6) who are assessed as grade A according to Child-Pugh classification must be taken the clinical stability was ≥ 28 days before taking the experimental drug; while patients with moderate liver impairment (Child-Pugh score: 7-9) who are assessed as grade B according to Child-Pugh classification must be taken the clinical stability was ≥ 14 days before taking the experimental drug;
  • Patients who have stable medication regimen for liver impairment, complications and other concomitant diseases within at least 28 days before taking the experimental drug, and the medication does not need to be adjusted (including drug type, dosage or frequency) during the clinical trials; or those who do not use the drug;
  • The function of vital organs meets the following criteria: (ANC) ≥ 1.0 × 109 / L (1000 / mm3); (Hgb) ≥ 9.0 g / dL (90g / L); ≥ 75.0 × 109 / L (75000 / mm3); rate (CLcr) ≥ 80 mL / min; The corrected (QTcF) was less than 450 msec (male);
  • In addition to liver impairment and complications, the investigator judged good condition according to the history inquiry, vital signs, physical examination, routine laboratory examination, 12-lead , abdominal ultrasound scan, EEG, etc., and there was no other abnormality;
  • Male subjects are willing to have no family planning during the trial and within 6 months after the last administration of the trial drug, and voluntarily take effective measures, or have undergone surgical sterilization.

Exclusion criteria

Exclusion Criteria:

-

Participants with mild to moderate liver impairment who meet any of the following criteria will not be eligible for this study:

  • Subjects had any of the following conditions: Patients with hepatic encephalopathy (according to score); previous liver transplantation; severe portal hypertension or portal systemic shunt; suspected or diagnosed liver cancer or other malignant tumors; liver failure patients; esophageal and gastric variceal bleeding; severe / advanced ascites; hepatorenal syndrome patients; biliary tract Liver cirrhosis, biliary obstruction, cholestatic liver disease and other diseases that seriously affect bile excretion;
  • In addition to the diseases leading to the diagnosis of liver impairment, the patients with severe acute and chronic diseases of other important organs within one year before screening, including but not limited to neuropsychiatric, digestive tract, respiratory system, urinary, endocrine, blood, immune and other diseases, were judged by the researchers to be unsuitable for the trial;
  • Any of the following conditions occurred within 6 months prior to the study: myocardial infarction, congenital long syndrome, torsade de pointes (including persistent ventricular tachycardia and ventricular fibrillation), right bundle branch block and left anterior half block (bifascilar block), unstable angina pectoris, coronary / peripheral artery bypass grafting, and congestive heart failure syndrome (Grade III or IV according to ), cerebrovascular accident, , or pulmonary embolism;
  • Patients who had serious gastrointestinal diseases (except secondary gastrointestinal diseases caused by hepatitis) or had digestive system surgery 3 months before screening, and the researchers considered that drug absorption was affected;
  • Warfarin or related coumarins were used for anticoagulant therapy within one month before screening, or warfarin or related coumarins were required for anticoagulant therapy during the trial period;
  • During the screening period, liver function fluctuations (such as active hepatitis), rapid deterioration (such as advanced ascites, fever, active gastrointestinal bleeding), grade 2 or above, ongoing arrhythmia, and atrial fibrillation of any level occurred;
  • People with allergic constitution, including those with severe drug allergy or history of drug allergy, and patients known to be allergic to the study drug SHR3680 or any of the product;
  • Those who have a history of drug use, or have a history of drug abuse in the past five years, or have a positive drug screening (except those with drug screening positive due to concomitant drug use);
  • HIVAb positive, syphilisAb positive;
  • Patients who have taken any clinical trial drugs within 3 months before screening; 14) Patients who had received drugs with definite potential hepatotoxicity and used them continuously for 7 days or more within 3 months before taking experimental drug;
  • In 2 weeks before screening, they used traditional Chinese medicine (Chinese herbal medicine, Chinese patent medicine), dietary supplements and vitamins;
  • Subjects with other factors not suitable to participate in this study were considered by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Healthy participants

    Intervention: Drug: SHR3680 single dose

    Drug: SHR3680

  • Experimental
    Mild liver impairment

    Intervention: Drug: SHR3680 single dose

    Drug: SHR3680

  • Experimental
    Moderate liver impairment

    Intervention: Drug: SHR3680 single dose

    Drug: SHR3680

Interventions

  • SHR3680, PO, single dose

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum concentration

    Time frame: Day1~Day29

  2. AUC0-t

    Area under the concentration time curve from time zero to time t

    Time frame: Day1~Day29

  3. AUC0-∞

    Area under the concentration time curve extrapolated to infinity

    Time frame: Day1~Day29

07

Study locations

1 of 1 sites recruiting
  • Guangzhou Eighth People'S Hospital
    GuangZhou, Guangdong 510060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Jul 2023, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2020
First posted
Nov 17, 2020
StartActual
Feb 3, 2021
Primary completionEst.
Jul 2023
CompletionEst.
Jul 2023
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04631549
Responsible party
Sponsor
First posted
Nov 17, 2020
Start date
Feb 3, 2021
Primary completion
Jul 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
Dec 1, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezvilutamide

Start the discussion